131 related articles for article (PubMed ID: 10965934)
1. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
[TBL] [Abstract][Full Text] [Related]
2. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.
Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC
Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197
[TBL] [Abstract][Full Text] [Related]
3. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
5. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
Legler UF
Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
[TBL] [Abstract][Full Text] [Related]
6. Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.
Leövey A; Bakó G; Szabó J; Kálmán K; Fórizs E
Acta Med Hung; 1992-1993; 49(3-4):179-85. PubMed ID: 1345455
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
9. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
10. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
[TBL] [Abstract][Full Text] [Related]
11. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
[TBL] [Abstract][Full Text] [Related]
12. [Steroid therapy for Graves' ophthalmopathy].
Hiromatsu Y
Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
[TBL] [Abstract][Full Text] [Related]
13. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
15. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.
Morishita E; Hashimoto T; Asakura H; Saito M; Yamazaki M; Aoshima K; Yoshida T; Kato H; Matsuda T
Thromb Haemost; 1998 May; 79(5):919-23. PubMed ID: 9609221
[TBL] [Abstract][Full Text] [Related]
16. Differential metabolic responses to tumor necrosis factor with increase in age.
Mondon CE; Starnes HF
Metabolism; 1992 Sep; 41(9):970-81. PubMed ID: 1518426
[TBL] [Abstract][Full Text] [Related]
17. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
[TBL] [Abstract][Full Text] [Related]
18. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
19. Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease.
Kubota S; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Kuma K; Miyauchi A
Endocr J; 2005 Dec; 52(6):735-41. PubMed ID: 16410666
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
